Transformation Resistance in a Premature Aging Disorder Identifies a Tumor-Protective Function of BRD4
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Advanced age and DNA damage accumulation are prominent risk factors for cancer. The premature aging disorder Hutchinson-Gilford progeria syndrome (HGPS) provides a unique opportunity for studying the interplay between DNA damage and aging-associated tumor mechanisms, given that HGPS patients do not develop tumors despite elevated levels of DNA damage. Here, we have used HGPS patient cells to identify a protective mechanism to oncogenesis. We find that HGPS cells are resistant to neoplastic transformation. Resistance is mediated by the bromodomain protein BRD4, which exhibits altered genome-wide binding patterns in transformation-resistant cells, leading to inhibition of oncogenic dedifferentiation. BRD4 also inhibits, albeit to a lower extent, the tumorigenic potential of transformed cells from healthy individuals. BRD4-mediated tumor protection is clinically relevant given that a BRD4 gene signature predicts positive clinical outcome in breast and lung cancer. Our results demonstrate a protective function for BRD4 and suggest tissue-specific roles for BRD4 in tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961 · cited 4×
“In agreement, inhibition of BRD4 alters select sets of genes in a tissue-specific manner (Dawson et al., 2011; Lovén et al., 2013; Nicodeme et al., 2010).”
InfluentialCreation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
Hoeijmakers, J. H. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804615 · Cited by 2,239
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870 · cited 2×
“…has a strong cancer-promoting role in hematopoietic malignancies (Dawson et al., 2011; Delmore et al., 2011; Mertz et al., 2011; Ott et al., 2012; Zuber et al., 2011) and has been implicated in breast cancer as an antimetastatic protein and in colon cancer as an antiproliferative factor…”
Suppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563 · cited 2×
“In agreement, inhibition of BRD4 alters select sets of genes in a tissue-specific manner (Dawson et al., 2011; Lovén et al., 2013; Nicodeme et al., 2010).”
Mutant nuclear lamin A leads to progressive alterations of epigenetic control in premature aging
Shumaker, D. K., Dechat, T., Kohlmaier, A., Adam, S. A., Bozovsky, M. R., Erdos, M. R., Eriksson, M., Goldman, A. E., Khuon, S., Collins, F. S., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602569103 · Cited by 791 · cited 4×
“Statistical significance (log rank test) is indicated in the graph plots. demonstrated to have altered histone modification landscapes including loss of H3K9me3 and altered acetylation patterns (McCord et al., 2013; Pegoraro et al., 2009; Scaffidi and Misteli, 2005; Shumaker et al., 2006).”
InfluentialHatzis, C. (2011) · JAMA · doi:10.1001/jama.2011.593 · Cited by 699
The cell nucleus and aging: tantalizing clues and hopeful promises
Scaffidi, P., Gordon, L., & Misteli, T. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030395 · Cited by 50
Self-citation
Cited by
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
“On the other hand, it could also be associated with more severe side effects, as BRD4 regulates diverse biological processes in a cellular context-dependent manner (Bolden et al., 2014; Fernandez et al., 2014).”
BackgroundRepression of the Antioxidant NRF2 Pathway in Premature Aging
Kubben, N., Zhang, W., Wang, L., Voss, T. C., Yang, J., Qu, J., Liu, G.-H., & Misteli, T. (2016) · Cell · doi:10.1016/j.cell.2016.05.017 · Cited by 489
Self-citationBET Proteins as Targets for Anticancer Treatment
Stathis, A., & Bertoni, F. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0605 · Cited by 463
“Finally, a tumor-suppressor role for BET proteins has also been reported in which their inhibition would result in a reduced immune surveillance (86) and reduced capacity of healthy cells to counteract the neoplastic transformation process (87).”
BackgroundBRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance
Tasdemir, N., Banito, A., Roe, J.-S., Alonso-Curbelo, D., Camiolo, M., Tschaharganeh, D. F., Huang, C.-H., Aksoy, O., Bolden, J. E., Chen, C.-C., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0217 · Cited by 415
“dedifferentiation in human breast cancer cells and cells from patients with premature aging syndrome (69, 70), and promotes hyperproliferation in the murine epidermis (71).”
Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity
Wainwright, E. N., & Scaffidi, P. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.04.004 · Cited by 342
Self-citation
Metadata
- Authors
- Fernandez, P., Scaffidi, P., Markert, E., Lee, J.-H., Rane, S., & Misteli, T.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 9
- Issue
- 1
- Pages
- 248-260
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2131378022
- Cited by
- 67
- References
- 9
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.